Date:7/23/2009

iod. Factors that could cause actual results to differ materially from those expressed in any forward-looking statement include, but are not limited to: the outcome and costs associated with the Company's Quality Process Improvement Project; the outcome of the administrative action ("notice of intent to revoke our biological license") received by the FDA; customer reaction to the FDA action and the subsequent impact on the business; lower than expected demand for the Company's instruments; the decision of customers to defer capital spending; the unexpected change in the mix of instruments being purchased instead of acquired through other means, which could significantly change costs recognized in the period; the inability of customers to efficiently integrate the Company's instruments into their blood banking operations; increased competition in the sale of instruments and reagents, particularly in North America; unanticipated operational problems that result in non-compliance with FDA regulations; the failure to effectively integrate BioArray operations into the Company's overall operations; product development obstacles including obstacles related to the Galileo Neo as well as the next generation automated instrument for the molecular immunohematology products; regulatory obstacles including obstacles in securing regulatory approval of the BioArray technology; the inability to hire and retain, and the unexpected loss of key managers; changes in interest rates; fluctuations in foreign currency conversion rates; the strengthening of the U.S. Dollar versus any of the functional currencies in which the Company operates and its adverse impact on reported results; the inability of the Company's Japanese, French and United Kingdom subsidiaries to attain expected revenue, gross margin and net income levels; the outcome of any legal claims or regulatory investigations known or unknown, including the ongoing investigations by the Department of Justice and Federal Trade Com
'/>"/>

SOURCE Immucor, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. Immucor Appoints Chief Operating Officer
2. Immucor Submits 10-Day Response to FDA; Establishes Product Surveillance and Improvement Department
3. Immucor to Announce Fiscal Fourth Quarter Financial Results on Thursday, July 23, 2009
4. Immucor Announces Fiscal Year 2010 Guidance
5. Immucor to Announce Fiscal 2010 Guidance on Monday, June 1, 2009
6. Immucor to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
7. Immucor Receives Subpoena From Department of Justice
8. Immucor Announces Fiscal Third Quarter Results
9. Immucor Announces New Vice President, Operations
10. Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance
11. Immucor Closes BioArray Acquisition